[EN] COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS [FR] COMPOSÉS UTILES EN TANT QUE MODULATEURS DE L'AUTOPHAGIE À MÉDIATION PAR DES CHAPERONES
RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS AND USES THEREOF
申请人:ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
公开号:US20150166492A1
公开(公告)日:2015-06-18
Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RARα) in subjects in need thereof.
Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
申请人:ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
公开号:US10189827B2
公开(公告)日:2019-01-29
Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RARα) in subjects in need thereof.
COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS
申请人:Albert Einstein College of Medicine
公开号:EP3844155A1
公开(公告)日:2021-07-07
RETINOIC ACID RECEPTOR ANTAGONISTS AS CHAPERONE-MEDIATED AUTHOPHAGY MODULATORS AND USES THEREOF
申请人:ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
公开号:US20170037039A1
公开(公告)日:2017-02-09
Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RARα) in subjects in need thereof.
BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS
申请人:Albert Einstein College of Medicine
公开号:US20210387953A1
公开(公告)日:2021-12-16
Compounds and pharmaceutically acceptable salts thereof of Formula I are disclosed. The variables, e.g. R
1
-R
9
, X, and Y are defined herein. Certain compounds and salts of Formula I are active as CMA modulators. The disclosure provides pharmaceutical compositions containing a compound of Formula I and methods of treating disorders responsive to CMA modulation.